AKEBIA THERAPEUTICS, INC. Increase (Decrease) in Other Noncurrent Assets
AKEBIA THERAPEUTICS, INC. (AKBA) reported Increase (Decrease) in Other Noncurrent Assets of $710.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentAssets · last filed 2026-08-05
- AKEBIA THERAPEUTICS, INC. increase (decrease) in other noncurrent assets for the quarter ending 2026-06-30 was -$39.00K.
- AKEBIA THERAPEUTICS, INC. increase (decrease) in other noncurrent assets for the quarter ending 2026-03-31 was $749.00K.
- AKEBIA THERAPEUTICS, INC. increase (decrease) in other noncurrent assets for the quarter ending 2025-12-31 was $2.76M, a 92000.00% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. increase (decrease) in other noncurrent assets for the quarter ending 2025-09-30 was -$38.00K.
- AKEBIA THERAPEUTICS, INC. increase (decrease) in other noncurrent assets for fiscal 2025 was $2.62M.
- AKEBIA THERAPEUTICS, INC. increase (decrease) in other noncurrent assets for fiscal 2024 was -$622.00K, a 145.70% decline from fiscal 2023.
- AKEBIA THERAPEUTICS, INC. increase (decrease) in other noncurrent assets for fiscal 2023 was $1.36M, a 75.80% decline from fiscal 2022.
- AKEBIA THERAPEUTICS, INC. increase (decrease) in other noncurrent assets for fiscal 2022 was $5.62M.
| Period end | Increase (Decrease) in Other Noncurrent Assets 3 month | Increase (Decrease) in Other Noncurrent Assets 3 month as first filed | Increase (Decrease) in Other Noncurrent Assets 6 month | Increase (Decrease) in Other Noncurrent Assets 6 month as first filed | Increase (Decrease) in Other Noncurrent Assets 9 month | Increase (Decrease) in Other Noncurrent Assets 9 month as first filed | Increase (Decrease) in Other Noncurrent Assets 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$39.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $710.00K 10-Q · filed 2026-08-05 | $3.47M derived: sum of 3 quarters · filed 2026-08-05 | $3.44M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2026-03-31 | $749.00K 10-Q · filed 2026-05-07 | $3.51M derived: sum of 2 quarters · filed 2026-05-07 | $3.47M derived: sum of 3 quarters · filed 2026-05-07 | $3.42M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-12-31 | $2.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.73M derived: sum of 2 quarters · filed 2026-02-26 | $2.68M derived: sum of 3 quarters · filed 2026-08-05 | $2.62M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | -$38.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$87.00K derived: sum of 2 quarters · filed 2026-08-05 | -$141.00K 10-Q · filed 2025-11-10 | -$138.00K derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-06-30 | -$49.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$103.00K 10-Q · filed 2026-08-05 | -$100.00K derived: sum of 3 quarters · filed 2026-08-05 | -$273.00K derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-03-31 | -$54.00K 10-Q · filed 2026-05-07 | -$51.00K derived: sum of 2 quarters · filed 2026-05-07 | -$224.00K derived: sum of 3 quarters · filed 2026-05-07 | -$1.29M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$170.00K derived: sum of 2 quarters · filed 2026-02-26 | -$1.24M derived: sum of 3 quarters · filed 2026-02-26 | -$622.00K 10-K · filed 2026-02-26 | |||
| 2024-09-30 | -$173.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$1.24M derived: sum of 2 quarters · filed 2025-11-10 | -$625.00K 10-Q · filed 2025-11-10 | -$7.44M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-06-30 | -$1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$452.00K 10-Q · filed 2025-08-07 | -$7.27M derived: sum of 3 quarters · filed 2026-02-26 | -$4.97M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-03-31 | $613.00K 10-Q · filed 2025-05-08 | -$6.20M derived: sum of 2 quarters · filed 2026-02-26 | -$3.90M derived: sum of 3 quarters · filed 2026-02-26 | -$838.00K derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2023-12-31 | -$6.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$4.51M derived: sum of 2 quarters · filed 2026-02-26 | -$1.45M derived: sum of 3 quarters · filed 2026-02-26 | $1.36M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $2.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $5.36M derived: sum of 2 quarters · filed 2024-11-07 | $8.18M 10-Q · filed 2024-11-07 | $34.83M derived: sum of 4 quarters · filed 2024-11-07 | |||
| 2023-06-30 | $3.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $5.88M 10-Q · filed 2024-08-08 | $32.53M derived: sum of 3 quarters · filed 2024-08-08 | $21.51M derived: sum of 4 quarters · filed 2024-08-08 | |||
| 2023-03-31 | $2.81M 10-Q · filed 2024-05-09 | $29.47M derived: sum of 2 quarters · filed 2024-05-09 | $18.45M derived: sum of 3 quarters · filed 2024-05-09 | $12.40M derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | $26.65M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $15.63M derived: sum of 2 quarters · filed 2024-03-14 | $9.59M derived: sum of 3 quarters · filed 2024-03-14 | $5.62M 10-K · filed 2024-03-14 | |||
| 2022-09-30 | -$11.02M derived: 10-Q 9 month − 10-K/A 6 month · filed 2023-11-08 | -$17.07M derived: sum of 2 quarters · filed 2023-11-08 | -$21.03M 10-Q · filed 2023-11-08 | -$14.82M 10-Q · filed 2022-11-03 | -$21.98M derived: sum of 4 quarters · filed 2023-11-08 | ||
| 2022-06-30 | -$6.05M derived: 10-K/A 6 month − 10-K/A 3 month · filed 2023-08-28 | -$10.01M 10-K/A · filed 2023-08-28 | -$9.35M 10-Q · filed 2022-08-04 | -$10.96M derived: sum of 3 quarters · filed 2023-08-28 | -$11.54M derived: sum of 4 quarters · filed 2023-08-28 | ||
| 2022-03-31 | -$3.97M 10-K/A · filed 2023-08-28 | -$3.30M 10-Q · filed 2022-05-09 | -$4.91M derived: sum of 2 quarters · filed 2023-08-28 | -$5.49M derived: sum of 3 quarters · filed 2023-08-28 | -$8.28M derived: sum of 4 quarters · filed 2023-08-28 | ||
| 2021-12-31 | -$946.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28 | -$1.52M derived: sum of 2 quarters · filed 2023-08-28 | -$4.31M derived: sum of 3 quarters · filed 2023-08-28 | -$5.67M 10-K/A · filed 2023-08-28 | |||
| 2021-09-30 | -$579.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$3.37M derived: sum of 2 quarters · filed 2022-11-03 | -$4.73M 10-Q · filed 2022-11-03 | -$8.47M derived: sum of 4 quarters · filed 2023-08-28 | |||
| 2021-06-30 | -$2.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$4.15M 10-Q · filed 2022-08-04 | -$7.89M derived: sum of 3 quarters · filed 2023-08-28 | -$1.31M derived: sum of 4 quarters · filed 2023-08-28 | |||
| 2021-03-31 | -$1.36M 10-Q · filed 2022-05-09 | -$5.10M derived: sum of 2 quarters · filed 2023-08-28 | $1.48M derived: sum of 3 quarters · filed 2023-08-28 | $1.46M derived: sum of 4 quarters · filed 2023-08-28 | |||
| 2020-12-31 | -$3.74M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28 | $2.84M derived: sum of 2 quarters · filed 2023-08-28 | $2.83M derived: sum of 3 quarters · filed 2023-08-28 | $2.78M 10-K/A · filed 2023-08-28 | |||
| 2020-09-30 | $6.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $6.56M derived: sum of 2 quarters · filed 2021-11-04 | $6.52M 10-Q · filed 2021-11-04 | $4.75M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-06-30 | -$11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$57.00K 10-Q · filed 2021-08-05 | -$1.83M derived: sum of 3 quarters · filed 2022-03-01 | -$1.60M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-03-31 | -$46.00K 10-Q · filed 2021-05-10 | -$1.82M derived: sum of 2 quarters · filed 2022-03-01 | -$1.59M derived: sum of 3 quarters · filed 2022-03-01 | -$4.24M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2019-12-31 | -$1.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$1.55M derived: sum of 2 quarters · filed 2022-03-01 | -$4.20M derived: sum of 3 quarters · filed 2022-03-01 | -$4.92M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | $226.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$2.43M derived: sum of 2 quarters · filed 2020-11-05 | -$3.15M 10-Q · filed 2020-11-05 | -$3.98M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2019-06-30 | -$2.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$3.37M 10-Q · filed 2020-08-10 | -$4.21M derived: sum of 3 quarters · filed 2021-02-25 | -$4.35M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2019-03-31 | -$719.00K 10-Q · filed 2020-05-05 | -$1.55M derived: sum of 2 quarters · filed 2021-02-25 | -$1.70M derived: sum of 3 quarters · filed 2021-02-25 | ||||
| 2018-12-31 | -$836.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$982.00K derived: sum of 2 quarters · filed 2021-02-25 | -$903.00K 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | -$146.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$67.00K 10-Q · filed 2019-11-12 | |||||
| 2018-06-30 | $79.00K 10-Q · filed 2019-08-08 | ||||||
| 2017-12-31 | $987.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $912.00K derived: sum of 2 quarters · filed 2020-03-12 | $990.00K derived: sum of 3 quarters · filed 2020-03-12 | $991.00K 10-K · filed 2020-03-12 | |||
| 2017-09-30 | -$75.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $3.00K derived: sum of 2 quarters · filed 2018-11-08 | $4.00K 10-Q · filed 2018-11-08 | ||||
| 2017-06-30 | $78.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $79.00K 10-Q · filed 2018-08-08 | |||||
| 2017-03-31 | $1.00K 10-Q · filed 2018-05-09 | ||||||
| 2016-12-31 | $2.00K 10-K · filed 2019-03-26 | ||||||
| 2015-12-31 | $976.00K 10-K · filed 2018-03-12 | ||||||
| 2014-12-31 | $179.00K 10-K · filed 2017-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |